Ignite Creation Date:
2025-12-25 @ 1:31 AM
Ignite Modification Date:
2025-12-25 @ 11:44 PM
Study NCT ID:
NCT06123494
Status:
RECRUITING
Last Update Posted:
2024-01-16
First Post:
2023-11-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-01-09
Start Date Type:
ACTUAL
Primary Completion Date:
2027-06-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2023-11-06
First Submit QC Date:
None
Study First Post Date:
2023-11-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-01-11
Last Update Post Date:
2024-01-16
Last Update Post Date Type:
ACTUAL